As an endogenous blocker, circNR3C1 binds to the BRD4 protein first, and then disconnects the formation of the BRD4/c-Myc complex, ending up inhibiting the progression of bladder cancer (Xie et al. 2020b). Here, MYC is linked to urinary bladder cancer.